Several days after it reported that it completed treating the last patient in the Phase I/IIa clinical trial of its BC-819 pancreatic cancer treatment, Biocancell Therapeutics Ltd. (TASE:BICL) said today that it successfully completed tests on animals ahead of continued development of the treatment.
The animal tests compared using BC-819 together with Gemzar (Gemcitabine), an US Food and Drug Administration (FDA)-approved drug to treat pancreatic cancer, as opposed to using Gemzar alone.
In animals treated with BC-819 and Gemzar, there was a significant reduction in the size of cancerous growths, compared with the group treated with Gemzar alone.
Biocancell believes that the tests point to the effectiveness of BC-819 in conjunction with other chemotherapy drugs in treating pancreatic cancer.
Biocancell shares rose 4.6% by early afternoon today.
Published by Globes [online], Israel business news - www.globes-online.com - on October 12, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010